The estimated Net Worth of Guido Magni is at least $31.7 Tausend dollars as of 7 October 2019. Guido Magni owns over 6,500 units of Aprea Therapeutics stock worth over $20,930 and over the last 5 years he sold APRE stock worth over $0. In addition, he makes $10,750 as Independent Director at Aprea Therapeutics.
Guido has made over 1 trades of the Aprea Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 6,500 units of APRE stock worth $97,500 on 7 October 2019.
The largest trade he's ever made was buying 6,500 units of Aprea Therapeutics stock on 7 October 2019 worth over $97,500. On average, Guido trades about 6,500 units every 0 days since 2019. As of 7 October 2019 he still owns at least 6,500 units of Aprea Therapeutics stock.
You can see the complete history of Guido Magni stock trades at the bottom of the page.
Dr. Guido Magni M.D., Ph.D. serves as Independent Director of the Company. Dr. Magni has been a Partner of Versant Ventures, a healthcare investment firm, since February 2012. Dr. Magni previously served as a Managing Director of EuroVentures Inc., a Versant Ventures biotechnology incubator, where he was intimately involved in several biotech investments, including Synosia Therapeutics Holding AG (sold to Biotie Therapies AG), Flexion Therapeutics, Inc. and Okairos AG. Dr. Magni was previously the Global Head of the Medical Science Department of Roche Pharmaceuticals (“Roche”) in Basel, Switzerland. During his twelve-year term at Roche, Dr. Magni oversaw the development and the registration of a large number of new chemical and biological entities including Cellcept, Pegasys, Mabthera, Xeloda, Herceptin, Tamiflu and Tarceva. Currently, Dr. Magni currently serves on the boards of Biotie Therapies AG and AM Pharma, with previous board positions at Adolor Corporation and Anabasis Pharma before their recent acquisitions. Dr. Magni was trained at the University of Padua with a specialization in neuro-psychiatry. He is the co-author of over 100 peer-reviewed papers.
As the Independent Director of Aprea Therapeutics, the total compensation of Guido Magni at Aprea Therapeutics is $10,750. There are 8 executives at Aprea Therapeutics getting paid more, with Christian Schade having the highest compensation of $3,677,570.
Guido Magni is 67, he's been the Independent Director of Aprea Therapeutics since 2016. There are no older and 17 younger executives at Aprea Therapeutics.
Over the last 5 years, insiders at Aprea Therapeutics have traded over $63,126,246 worth of Aprea Therapeutics stock and bought 2,073,560 units worth $29,606,912 . The most active insiders traders include Group, Llc Green Jeremy Red..., Vantage I, L.P.Versant Vant... und John B Iii Henneman. On average, Aprea Therapeutics executives and independent directors trade stock every 43 days with the average trade being worth of $420,918. The most recent stock trade was executed by John P. Hamill on 13 March 2024, trading 1,010 units of APRE stock currently worth $7,363.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Aprea Therapeutics executives and other stock owners filed with the SEC include: